Magenta Therapeutics (MGTA) Stock Analysis

What Magenta Therapeutics does

Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to MGTA

Broad-market and Healthcare sector ETFs an investor holding Magenta Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MGTA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Magenta Therapeutics?

Magenta Therapeutics trades under the ticker MGTA on NASDAQ.

Which exchange is MGTA listed on?

MGTA is listed on NASDAQ.

What sector does Magenta Therapeutics operate in?

Magenta Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MGTA in a portfolio?

PortView shows MGTA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.